Coherus Oncology Inc expected to post a loss of 22 cents a share - Earnings Preview
Coherus Oncology Inc CHRS.O is expected to show a rise in quarterly revenue when it reports results on November 9 for the period ending September 30 2026
The Redwood City California-based company is expected to report a 38.4% increase in revenue to $16.011 million from $11.57 million a year ago, according to the mean estimate from 6 analysts, based on LSEG data.
LSEG's mean analyst estimate for Coherus Oncology Inc is for a loss of 22 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Coherus Oncology Inc is $7.00, about 593.1% above its last closing price of $1.01
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2026 | -0.18 | -0.20 | -0.13 | Beat | 35 |
Mar. 31 2026 | -0.27 | -0.27 | -0.25 | Beat | 8.5 |
Dec. 31 2025 | -0.34 | -0.34 | Met | 1 | |
Sep. 30 2025 | -0.29 | -0.32 | -0.33 | Missed | -1.5 |
Jun. 30 2025 | -0.32 | -0.30 | -0.34 | Missed | -14.6 |
Mar. 31 2025 | -0.32 | -0.23 | -0.35 | Missed | -50.9 |
Dec. 31 2024 | -0.18 | -0.13 | -0.28 | Missed | -113.1 |
Sep. 30 2024 | -0.16 | -0.13 | -0.01 | Beat | 92.5 |
This summary was machine generated October 26 at 20:47 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)